Table 2. Content of activated lovastatin in sera of rats receiving lovastatin-encapsulating PLGA nanoparticles.

Healthy male Lewis rats received a single peri-neural injection of lovastatin-encapsulating PLGA nanoparticles and one week later sera levels of active lovastatin were analyzed by HPLC and found to be below the level of detection. For comparison, levels of activated lovastatin in sera of rats that received lovastatin prodrug as a single intraperitoneal bolus or by oral gavage, as indicated, are shown. In all cases, levels of the inactive lovastatin prodrug were below the level of detection. Data shown are the means ± SEM, n=3–6.

Dose and Route of Administration	Time	Lovastatin Hydroxy Acid (ng/ml)
10 mg/kg, intraperitoneal	1h	937.5 ± 50.4
100 mg/kg, oral gavage	1h	385.3 ± 53.7
20 mg of 25% w/w lovastatin-encapsulating nanoparticles	1 week	undetectable